Top

07-06-2017 | Biosimilars | Article

Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study

Journal: Clinical Rheumatology

Authors: E. M. H. Schmitz, S. Benoy - De Keuster, A. J. L. Meier, V. Scharnhorst, R. A. M. Traksel, M. A. C. Broeren, L. J. J. Derijks

Publisher: Springer London

Abstract

The objective of this study is to apply therapeutic drug monitoring (TDM) as an objective tool to monitor the switch from infliximab innovator (INX) to infliximab biosimilar (INB) in our diverse rheumatic cohort in daily clinical practice. All rheumatic patients on INX treatment (Remicade®) and ≥18 years were switched to INB (Inflectra®) as part of routine care, but in a controlled setting. Patients were monitored by taking blood samples just before the first infusion of INB (T1), and after the second (T2), fourth (T3), and seventh (T4) infusion of INB. T4 reflects the patients’ status after ∼12 months. Infliximab trough levels, antibodies-to-infliximab (ATI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and validated disease activity scores (if possible) were measured. Our population consisted of 27 patients with seven different rheumatic diseases who had received INX for 143 (58–161) months (median (IQR)). Half of the patients (52%) received concomitant immunosuppressives. We found widely varying infliximab levels, with only 56% within the proposed therapeutic range of 1–5 μg/mL. One patient had very high ATI levels (>880 au/mL), and two had low ATI levels (≤30 au/mL). After switching to INB, seven patients (26%) discontinued the therapy, partially due to subjective reasons. No difference in infliximab levels, CRP levels, and disease activity scores was found between the four time points (p ≥ 0.2460). In conclusion, no pharmacokinetic or clinical differences were found between INX and INB in our diverse rheumatic cohort. TDM is a helpful tool to monitor patients switching from INX to INB.

Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G et al (2013) The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatol Oxf Engl 52(7):1245–1253CrossRef

Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P et al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72(10):1605–1612CrossRefPubMedPubMedCentral

Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72(10):1613–1620CrossRefPubMedPubMedCentral

Park W, Lee SJ, Yun J, Yoo DH (2015) Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol 11(Suppl 1):S25–S31CrossRefPubMed

Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A et al (2015) A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 18:82CrossRef

Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, et al. (2016) Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 26

Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. (2016) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 29

Gils A (2017) Combining therapeutic drug monitoring with biosimilars, a strategy to improve the efficacy of biologicals for treating inflammatory bowel diseases at an affordable cost. Dig Dis Basel Switz 35(1–2):61–68CrossRef

Schmitz EMH, van de Kerkhof D, Hamann D, van Dongen JLJ, Kuijper PHM, Brunsveld L, et al. (2015) Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med CCLM FESCC 20

10.

Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711–715CrossRefPubMed

11.

Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P et al (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108(6):962–971CrossRefPubMed

12.

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O et al (2014) The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 63(8):1258–1264CrossRefPubMed

13.

Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP et al (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704–707CrossRefPubMed

14.

Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE et al (2016) Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD Open 2(2):e000272CrossRefPubMedPubMedCentral

15.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CLM, Turk S, Navarro-Compán V et al (2015) Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. J Rheumatol 42(9):1638–1646CrossRefPubMed

16.

Pascual-Salcedo D, Plasencia C, Jurado T, Valle LG del, Sabina P, Diego C, et al. Dose-tapering of TNF inhibitors in daily rheumatology practice enables the maintenance of clinical efficacy while improving cost-effectiveness. J Pharmacovigil [Internet]. 2015 Aug 5 [cited 2017]; Available from: https://www.esciencecentral.org/journals/dosetapering-of-tnf-inhibitors-in-daily-rheumatology-practice-enables-the-maintenance-of-clinical-efficacy-while-improving-costeffectiveness-2329-6887-1000172.php?aid=58635

17.

Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol Hoboken NJ 68(8):1810–1817CrossRef

18.

Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69(7):1286–1291CrossRefPubMedPubMedCentral

19.

den Broeder AA, van Herwaarden N, van der Maas A, van den Hoogen FHJ, Bijlsma JW, van Vollenhoven RF et al (2013) Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 14:299CrossRef

20.

Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. (2015) Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 1–7

21.

Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, Stefano RD et al (2016) Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Expert Opin Biol Ther 16(10):1311–1312CrossRefPubMed

22.

Tweehuysen L, van den Bemt B.J.F., van Ingen I.L., de Jong A.J.L., van der Laan W.H., van den Hoogen F.H.J., den Broeder A.A. Clinical and immunogenicity outcomes after switching treatment from innovator infliximab to biosimilar infliximab in rheumatic diseases in daily clinical practice [Internet]. ACR Meeting Abstracts. [cited 2017 Feb 16] Available from: http://acrabstracts.org/abstract/clinical-and-immunogenicity-outcomes-after-switching-treatment-from-innovator-infliximab-to-biosimilar-infliximab-in-rheumatic-diseases-in-daily-clinical-practice/

23.

Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V et al (2016) Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res 23

Medicine Matters Rheumatology

Abstract